MedPage Today - "ESC: Women Get Benefit From Drug-Eluting Stents"

In women, drug-eluting stents are safe and effective compared with bare-metal stents, and the observed benefit was greatest with newer-generation devices, a large meta-analysis showed.

New York, NY
 – September 3, 2013  –– 

In trials conducted since 2000, the rate of death or MI in women through about 3 years of follow-up was 12.8% with bare-metal stents, 10.9% with early-generation drug-eluting stents, and 9.2% with newer-generation drug-eluting stents (P=0.001), according to Roxana Mehran, MD, of the Icahn School of Medicine at Mount Sinai in New York City. And definite or probable stent thrombosis -- which Mehran called an "Achilles heel" of the first drug-eluting stents at her presentation at the European Society of Cardiology meeting here -- was 1.3% with bare-metal stents, 2.1% with early-generation drug-eluting stents, and 1.1% with the newer drug-eluting stents. "To the best of our knowledge, this study is the first comprehensive large-scale analysis of the safety and efficacy of drug-eluting stents in women," Mehran and her colleagues wrote in a paper simultaneously published in The Lancet.

- Dr. Roxana Mehran, Professor, Medicine, Cardiology, Director of Interventional Cardiovascular Research and Clinical Trials, Icahn School of Medicine at Mount Sinai

Learn More